Lyrica (Pregabalin) Korean Post Marketing Surveillance Study
Launched by PFIZER'S UPJOHN HAS MERGED WITH MYLAN TO FORM VIATRIS INC. · Oct 12, 2010
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
continuous patients with target disorders in collaborating institutions
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any patient treated with pregabalin for an approved indication by Korean Food and Drug Administration
- Exclusion Criteria:
- • Non-consenting
- • Hypersensitivity to the active substance or to any of the excipients
- • galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
About Pfizer's Upjohn Has Merged With Mylan To Form Viatris Inc.
Viatris Inc. is a global healthcare company formed from the merger of Pfizer's Upjohn division and Mylan, dedicated to providing access to high-quality medicines, including generics and specialty pharmaceuticals. With a strong commitment to innovation and patient-centric solutions, Viatris leverages a diverse portfolio and extensive global reach to address the evolving healthcare needs of patients worldwide. The company aims to create sustainable healthcare solutions by combining expertise in pharmaceutical development, manufacturing, and distribution, ultimately enhancing patient outcomes and improving overall health systems.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials